• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Acasti Pharma Inc.

    7/10/24 9:10:22 PM ET
    $ACST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACST alert in real time by email
    SC 13G 1 tm2419166d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

    ACASTI PHARMA INC.

    (Name of Issuer)

     

    Class A Common Stock, no par value

    (Title of Class of Securities)

     

    00430K865

    (CUSIP Number)

     

    June 28, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 00430K865

     

    1 Names of reporting persons
    ADAR1 Capital Management, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization   
    Texas

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    959,571
    7 Sole dispositive power
    0
    8 Shared dispositive power
    959,571

    9 Aggregate amount beneficially owned by each reporting person
    959,571 (*)(**)
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    10.20%
    12 Type of reporting person (see instructions)
    IA

     

    (*) The reported beneficial ownership does not include 913,631 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Pre-Paid Warrant Agreement with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    (**) The reported beneficial ownership does not include 1,268,195 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Common Stock Purchase Warrant with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    2

     

     

    SCHEDULE 13G

     

    CUSIP No. 00430K865

     

    1 Names of reporting persons
    ADAR1 Capital Management GP, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    Texas

    Number of
    shares
    beneficially
    owned by each reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    959,571
    7 Sole dispositive power
    0
    8 Shared dispositive power
    959,571

    9 Aggregate amount beneficially owned by each reporting person
    959,571 (*)(**)
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    10.20%
    12 Type of reporting person (see instructions)
    OO

     

    (*) The reported beneficial ownership does not include 913,631 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Pre-Paid Warrant Agreement with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    (**) The reported beneficial ownership does not include 1,268,195 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Common Stock Purchase Warrant with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    3

     

     

    SCHEDULE 13G

     

    CUSIP No. 00430K865

     

    1 Names of reporting persons
    Daniel Schneeberger
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    Switzerland

    Number of
    shares
    beneficially
    owned by each reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    959,571
    7 Sole dispositive power
    0
    8 Shared dispositive power
    959,571

    9 Aggregate amount beneficially owned by each reporting person
    959,571 (*) (**)
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    10.20%
    12 Type of reporting person (see instructions)
    IN

     

    (*) The reported beneficial ownership does not include 913,631 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Pre-Paid Warrant Agreement with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    (**) The reported beneficial ownership does not include 1,268,195 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Common Stock Purchase Warrant with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    4

     

     

    Item 1(a) Name of issuer:

     

    Acasti Pharma Inc. (the “Issuer”)

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    103 Carnegie Center, Suite 300, Princeton, New Jersey 08540

     

    Item 2(a) Name of person filing:

     

    This Statement is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

     

      i) ADAR1 Capital Management, LLC (“ADAR1 Capital Management”);

     

      ii) ADAR1 Capital Management GP, LLC (“ADAR1 General Partner”); and

     

      iii) Daniel Schneeberger (“Mr. Schneeberger”);

     

    This Statement relates to Shares (as defined herein) held for the accounts of ADAR1 Partners, LP (“ADAR1 Partners”). ADAR1 Capital Management acts as investment manager to, and manages investment and trading accounts of ADAR1 Partners. ADAR1 General Partner serves as the general partner of ADAR1 Partners, and Mr. Schneeberger is the sole member of ADAR1 Capital Management and ADAR1 General Partner. As such, each of ADAR1 Capital Management, ADAR1 General Partner and Mr. Schneeberger may be deemed the indirect beneficial owner of securities held by ADAR1 Partners.

     

    Each Reporting Person declares that neither the filing of this Statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

     

    Item 2(c) Citizenship:

     

      i) ADAR1 Capital Management is a Texas limited liability company;

     

    ii)ADAR1 General Partner is a Texas limited liability company; and

     

    iii)Mr.Schneeberger is a citizen of Switzerland.

     

    Item 2(d) Title of Class of Securities:

     

    Class A Common Stock, no par value (the “Shares”)

     

    5

     

     

    Item 2(e) CUSIP No.:

     

    00430K865

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
      (c) ¨ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 
         
      (e) xAn investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 
         
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 
         
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 
         
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 
         
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 
         
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4. Ownership

     

    (a) Amount Beneficially Owned:

     

    As of June 28, 2024, each of the Reporting Persons may be deemed the beneficial owner of 959,571(*)(**) Shares. This includes 959,571(*)(**) Shares held for the account of ADAR1 Partners.

     

    (*) The reported beneficial ownership does not include 913,631 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Pre-Paid Warrant Agreement with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    (**) The reported beneficial ownership does not include 1,268,195 of the Issuer’s Common Stock issuable upon exercise by ADAR1 pursuant to the terms of a Common Stock Purchase Warrant with the Issuer, which provides for a beneficial ownership limitation of 4.99%, which percentage may be changed to up to 19.99% at a holder’s election upon 61 days’ notice to the Issuer.

     

    (b) Percent of Class:

     

    As of June 28, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 10.20% of the Shares outstanding, based on 9,399,404 Shares outstanding as of May 31, 2024, according to the Issuer’s Form 10-K Annual Report, filed on June 21, 2024.

     

    6

     

     

    (c) Number of shares as to which such person has:

     

    As of June 28, 2024, for each of the Reporting Persons:

     

      (i) Sole power to vote or to direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 959,571

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of: 959,571

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    See disclosures in Items 2 and 4 hereof. ADAR1 Partners is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

     

    Dated: July 10, 2024

     

    ADAR1 CAPITAL MANAGEMENT, LLC
     
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management, LLC  

     

    ADAR1 CAPITAL MANAGEMENT GP, LLC
     
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management GP, LLC  

     

    DANIEL SCHNEEBERGER
     
    /s/ Daniel Schneeberger  

     

    8

     

     

    EXHIBIT INDEX

     

    Exhibit   Page No.
    A.  Joint Filing Agreement   1

     

    9

     

    Get the next $ACST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACST

    DatePrice TargetRatingAnalyst
    12/22/2021$6.00Outperform
    Oppenheimer
    12/21/2021$6.00Outperform
    Oppenheimer
    More analyst ratings

    $ACST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Grace Therapeutics to Participate in Upcoming Investor Events January 2025

      PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will participate the following investor and industry networking events during the month of January 2025. 14th Annual LifeSci Partners Corporate Access Event – (January 13, 2025) BIO One-on-One Partnering™ – (Ja

      1/7/25 8:00:00 AM ET
      $ACST
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

      PRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that the Company will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists (ASHP) to be held December 8–12, 2024, in New Orleans, LA. "As we look forward to data readout from our Phase 3 STRIVE-ON trial

      12/4/24 8:00:00 AM ET
      $ACST
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

      Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics).

      10/25/24 8:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kavuru Vimal bought $1,249,934 worth of shares (676,371 units at $1.85) (SEC Form 4)

      4 - Acasti Pharma Inc. (0001444192) (Issuer)

      9/27/23 7:46:45 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Acasti Pharma Inc.

      SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

      7/10/24 9:10:22 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acasti Pharma Inc.

      SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

      4/9/24 8:46:48 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acasti Pharma Inc.

      SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

      2/13/24 7:03:33 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Leadership Updates

    Live Leadership Updates

    See more
    • Acasti Announces Appointment of New Scientific Advisory Board Members

      LAVAL, QC, June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced the appointment of W. Taylor Kimberly, MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board. "We are extremely pleased to add eminent physicians with a deep understanding of aSAH and neurocritical care to the Acasti Scientific Advisory Board," commented Prashant Kohli, CEO of Acasti. "As we continue to focus our efforts squarely on the advanc

      6/22/23 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Announces Appointment of Prashant Kohli as CEO

      LAVAL, QC, April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, today announced the appointment of Prashant Kohli as Acasti's new Chief Executive Officer, succeeding Jan D'Alvise. The parties have mutually agreed to part ways, and Ms. D'Alvise will be stepping down from the board. Prashant Kohli has served as Chief Commercial Officer of Acasti since 2022. Mr. Kohli has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Recently, Mr. Kohli was VP, Commercial Operations of Acasti and at Grace Therapeutics, p

      4/4/23 8:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

      LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated August 31, 2022 (the "Proxy Statement"), being Jean Marie (John) Canan, Jan D'Alvise, Donald Olds, Vimal Kavuru and Michael L. Derby were elected as directors of Acasti at the Meeting to serve for a te

      9/29/22 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Acasti Pharma with a new price target

      Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00

      12/22/21 5:05:43 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Acasti Pharma with a new price target

      Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00

      12/21/21 4:57:37 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    SEC Filings

    See more
    • Acasti Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      10/28/24 8:22:47 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Acasti Pharma Inc. (0001444192) (Filer)

      10/25/24 8:13:49 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Acasti Pharma Inc.

      EFFECT - Acasti Pharma Inc. (0001444192) (Filer)

      10/16/24 12:15:09 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Financials

    Live finance-specific insights

    See more
    • Acasti Pharma Reports Third Quarter 2023 Operational Results

      Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the third quarter ended December 31, 2022 Recent Highlights The Company anticipates receiving clarifying guidance from the Food and Drug Administration (FDA) on its proposed phase 3 study design for GTX-104 through a written Type C meeting in the first calendar quarter of 2023. The Company expects that favorable FDA guidance would allow Acasti

      2/14/23 7:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

      Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time LAVAL, QB, Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, February 14, 2023, to discuss the Company's corporate progress and other developments, as well as financial results for third quarter 2023 ended December 31, 2022. The conference call will be a

      2/7/23 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

      LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures. The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers. A webca

      1/5/23 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: New insider Adar1 Capital Management, Llc claimed ownership of 959,571 shares (SEC Form 3)

      3/A - Acasti Pharma Inc. (0001444192) (Issuer)

      7/11/24 11:16:42 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Adar1 Capital Management, Llc claimed ownership of 959,571 shares (SEC Form 3)

      3 - Acasti Pharma Inc. (0001444192) (Issuer)

      7/9/24 8:29:48 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by D'Andrea Carrie (Amendment)

      4/A - Acasti Pharma Inc. (0001444192) (Issuer)

      5/10/24 4:11:36 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care